Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.

@article{Laine2003EffectsOE,
  title={Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.},
  author={Kari Laine and Tuija Heikkinen and Ulla Ekblad and Pentti O. Kero},
  journal={Archives of general psychiatry},
  year={2003},
  volume={60 7},
  pages={
          720-6
        }
}
BACKGROUND Selective serotonin reuptake inhibitors (SSRIs) have gained wide acceptance in the treatment of mental disorders in pregnant women, but there seems to be an increased risk for neonatal adaptation problems after exposure to SSRIs in late pregnancy. We aimed to investigate the perinatal sequelae of infants exposed to SSRIs during their fetal life and the relationship of these symptoms to the cord blood monoamine and prolactin concentrations. METHODS We conducted a prospective… Expand
Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development
TLDR
Evidence is provided that the length of prenatal SSRI antidepressant use can affect neonatal adjustment and can have an effect on psychomotor test scores in infancy. Expand
FETAL EFFECTS OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR TREATMENT DURING PREGNANCY: IMMEDIATE AND LONGER TERM CHILD OUTCOMES
TLDR
Clinical research is brought together that examines the immediate and longer term physical and developmental risks to the child that may be associated with prenatal exposure to SSRIs and the methodological issues that may contribute to conflicting findings. Expand
Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates
OBJECTIVES. Our goals were to (a) describe neonatal behavioral signs in a group of newborns exposed in utero to selective serotonin reuptake inhibitors or venlafaxine at the time of delivery, (b)Expand
Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy
TLDR
Pregnant women who require treatment for depression and their physicians often face a difficult choice regarding the use of SSRIs, as the possibility of such functional abnormalities is an additional concern. Expand
Selective Serotonin Reuptake Inhibitors Affect Neurobehavioral Development in the Human Fetus
TLDR
The results demonstrate changes in fetal neurobehavioral development associated with standard and high SSRI dosages that are observable throughout gestation. Expand
Safety of selective serotonin reuptake inhibitors in pregnancy.
TLDR
The review tries to clarify the blurred aspects of the use of SSRI during pregnancy and to give sensible and up-to-dated guidelines for the treatment of psychiatric disorders with SSRIs during pregnancy. Expand
In Utero Exposure to Selective Serotonin Reuptake Inhibitors: Evidence for Poor Neonatal Adaptation
TLDR
This article will critically evaluate the literature regarding perinatal outcomes for infants exposed to SSRI/SNRIs in utero, suggesting practice implications for nursing, medical care, and family education and support for those exposed. Expand
Selective serotonin reuptake inhibitors in pregnancy.
TLDR
The literature on effects of SSRIs on embryonic, fetal and infant development is reviewed and potential risks must be balanced against the effects of untreated maternal depression. Expand
Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?
TLDR
Recommendations to taper the dosage of antidepressants in pregnant women during the last trimester are only partially evidence-based and may put the depressed mother-to-be and her baby at an unreasonable health risk. Expand
Prenatal exposure to selective serotonin reuptake inhibitors (SSRI) increases aggression and modulates maternal behavior in offspring mice.
TLDR
The results indicate that in utero FLX increased aggression in adult males and delayed emergence of maternal behavior in adult females, and the notion that alterations in the development of serotonergic pathways following prenatal exposure to SSRIs are associated with changes in social and maternal behavior throughout life is supported. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors
TLDR
Five cases of neonatal withdrawal syndrome after third trimester in utero SSRI exposure are reported, with Symptoms were irritability, constant crying, shivering, increased tonus, eating and sleeping difficulties and convulsions. Expand
Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
TLDR
The new SSRIs, fluvoxamine, paroxetine, and sertraline, do not appear to increase the teratogenic risk when used in their recommended doses. Expand
Neurodevelopment of children exposed in utero to antidepressant drugs.
TLDR
In utero exposure to either tricyclic antidepressant drugs or fluoxetine does not affect global IQ, language development, or behavioral development in preschool children. Expand
Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission
TLDR
The present results therefore support animal experimental data suggesting that SSRIs produce a delayed increase in some aspects of brain serotonin neurotransmission. Expand
Birth outcomes following prenatal exposure to fluoxetine
TLDR
Patients may be best advised to continue treatment with antidepressants through labor and delivery versus making any change in intensity of treatment during the acute peripartum period. Expand
Delivery outcome after the use of antidepressants in early pregnancy
TLDR
The use of antidepressants in early pregnancy does not seem to carry any significant risk for the infant that is detectable during the newborn period, based on this database. Expand
Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn.
TLDR
This statement will limit its scope to drug selection guidelines for those psychoactive agents used during pregnancy for prevention or treatment of the following common psychiatric disorders: schizophrenia, major depression, bipolar disorder, panic disorder, and obsessive-compulsive disorder. Expand
Pregnancy Outcome Following First-Trimester Exposure to Fluoxetine (Prozac)
TLDR
This study suggests that the use of fluoxetine during embryogenesis is not associated with an increased risk of major malformations, and suggests that long-term studies will be warranted to rule out potential developmental teratology of fluxetine, which affects a central nervous system neurotransmitter. Expand
Lack of adverse interactions between concomitantly administered selegiline and citalopram.
TLDR
The present results indicate lack of clinically relevant pharmacodynamic or pharmacokinetic interactions between selegiline and citalopram. Expand
Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
  • J. Hyttel
  • Biology, Medicine
  • International clinical psychopharmacology
  • 1994
TLDR
Since the marketed SSRIs all show clear antidepressant effect, this receptor regulation seems not to be a prerequisite for clinical antidepressant activity. Expand
...
1
2
3
4
...